Key result
Repeated grazoprevir, elbasvir, and sofosbuvir yields virologic and partial remission in HCV cryoglobulinemic vasculitis.
Case Report (n=1)
Grazoprevir, elbasvir, and sofosbuvir can successfully treat hepatitis C genotype 1b with D168E and L31V mutations and cryoglobulinemic vasculitis after daclatasvir/asunaprevir failure.
Hypothesis-generating for retreatment in resistant HCV vasculitis; prospective trials needed before broader adoption.
The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development of mixed type III cryoglobulinemia, cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic vasculitis), and the liver (alternatively proliferative vasculitis) is demonstrated. The introduction of daclatasvir + asunaprevir was virologically unsuccessful: mutations D168E and L31V were detected against the background of a virological breakthrough. A repeated course of antiviral therapy with the combination of Grazoprevir + Elbasvir in combination with sofosbuvir led to a stable virologic response, partial immunological and clinical remission.
No takes yet. Share an insight, caveat, or question.
Дунаева et al. (2020) conducted a case report in Chronic hepatitis C 1b genotype with cryoglobulinemic vasculitis (n=1). Grazoprevir + Elbasvir in combination with sofosbuvir was evaluated on Virologic response and clinical remission. A repeated course of antiviral therapy with Grazoprevir, Elbasvir, and sofosbuvir led to a stable virologic response and partial clinical remission in a patient with HCV and cryoglobulinemic vasculitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: